1 / 2

Multiple Myeloma Newsletter, Multiple Myeloma market, Multiple Myeloma market size, Multiple Myeloma market share, Mult

Multiple myeloma (MM) is a cancer of the blood that begins in the bone marrow. In myeloma, plasma cells develop into cancerous myeloma cells. Multiple myeloma is not widespread cancer; however, it has come to be considered as the second most widely diagnosed blood cancer in the United States.<br><br>https://www.delveinsight.com/whitepaper-newsletter/multiple-myeloma-newsletter

yashb
Download Presentation

Multiple Myeloma Newsletter, Multiple Myeloma market, Multiple Myeloma market size, Multiple Myeloma market share, Mult

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 1 MULTIPLE MYELOMA Newsletter Industry and Updated News Multiple myeloma is a malignant disorder characterized by uncontrolled proliferation of clonal plasma cells causing a wide variety of complications leading to organ dysfunction and eventually death. It is the second most prevalent hematological malignancy worldwide, with a median onset of 60 years. This incurable malignancy develops from an accumulation of terminally differentiated monoclonal plasma cells (PC) in the bone marrow. In the United States, the lifetime risk for MM is 1 in 143 (0.7%). The majority of patients with multiple myeloma (MM) will have an initial response to treatment with modern combination regimens. However, conventional therapy is not curative and most of these patients will ultimately progress. In addition, some patients will not respond to initial treatment (i.e., refractory disease). Relapsed or refractory MM is usually identified through routine monitoring with laboratory studies. The signs and symptoms of Multiple Myeloma include hypercalcemia, renal insufficiency, anemia, lytic bony lesions along with a monoclonal protein in the serum, increase in the number of clonal plasma cells in the bone marrow, etc.

  2. 2 #DelveInsight, through its newsletter series, aims for increased awareness about the indication, its underlying causes, etiology, symptoms, and risk factors among its readers. Have a Copy our Newsletter-- https://www.delveinsight.com/whitepaper- newsletter/multiple-myeloma-newsletter Know More About What's Covered: · Indication overview · Signs, symptoms, and diagnosis · Epidemiological trends · Treatment approaches · Unmet needs · Market insights · Key Companies · Clinical trials · R&D in the field · Top conferences · Support from International organizations · Collaborations and deals in the domain Have a Copy our Newsletter-- https://www.delveinsight.com/whitepaper- newsletter/multiple-myeloma-newsletter #raredisease #rare #disease #medicalsciences #newsletter #promotion #covid19 #healthcare #business #multiplemyeloma #readerscommunity #readinglist #newsletterdesign

More Related